25 completed. 25 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 3 | Completed 3 |
Follow Muscle Spasticity: new trials by email Literature Review of Muscle Spasticity trials Research Report on Muscle Spasticity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Photobiomodulation and Tretament of Spasticity Photobiomodulation, Institution's Standard Physiotherapy, Photobiomodulation Placebo - Muscle Spasticity, Cerebral Palsy | Phase 2 / Phase 3 | Completed | University of Nove de Julho | 12 | 2023-08-15 | 2026-05-01 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke sham Doublestim, anodal Doublestim - Stroke, Cerebrovascular Accident (CVA) | Phase 1 / Phase 2 | Completed | Northwell Health | 26 | 2016-09-01 | 2021-04-05 |
| Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Botulinum Toxin Injections, Placebo Injections - Hereditary Spastic Paraplegia | Phase 2 / Phase 3 | Completed | University of Campinas, Brazil | 55 | 2016-03-09 | 2017-11-07 |
| Developing and Testing a Comprehensive MS Spasticity Management Program Spasticity: Take Control, Usual care - Multiple Sclerosis, Spasticity | Phase 2 | Completed | VA Office of Research and Development | 40 | 2015-10-01 | 2017-03-28 |
| Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis VSN16R, Placebo - Spasticity in People With Multiple Sclerosis | Phase 2 | Completed | Canbex Therapeutics Ltd | 160 | 2015-08-01 | 2018-03-02 |
| Powered Exoskeleton for the Treatment of Elbow Spasticity Robotic treatment - Muscle Spasticity, Stroke | Phase 2 | Completed | Auxilium Vitae Volterra | 20 | 2014-07-01 | 2018-07-26 |
| Study of SPARC1103 in Subjects With Spasticity SPARC1103 low dose, SPARC1103 high dose, SPARC Placebo - Spasticity | Phase 2 | Completed | Sun Pharma Advanced Research Company Limited | 142 | 2014-04-21 | 2019-05-03 |
| A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial Tizanidine, Placebo, Moxifloxacin - Spasticity | Phase 2 | Completed | Acorda Therapeutics | 136 | 2013-04-01 | 2021-03-23 |
| Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Cannabis Sativa extract Oromucosal spray - Motor Neuron Disease, Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | Ospedale San Raffaele | 60 | 2013-01-01 | 2017-03-09 |
| Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons nabilone 0.5 mg, placebo - Muscle Spasticity as a Result of Spinal Cord Injury | Phase 2 | Completed | University of Manitoba | 12 | 2012-06-01 | 2015-02-25 |
| Early Use of Botulinum Toxin in Spasticity Post Stroke. onabotulinumtoxinA, Placebo - Stroke, Muscle Spasticity | Phase 2 | Completed | Sandwell & West Birmingham Hospitals NHS Trust | 120 | 2012-01-01 | 2014-11-18 |
| rTMS and Conventional Physical Therapy After Stroke rTMS, conventional physical therapy - Stroke | Phase 2 | Completed | Universidade Federal de Pernambuco | 20 | 2011-11-01 | 2013-06-12 |
| The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI) LOKOMAT - Motor Complete Spinal Cord Injury | Phase 1 / Phase 2 | Completed | Dr. Gabriel Zeilig | 11 | 2011-05-01 | 2016-12-28 |
| A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis IPX056, Baclofen IR, Placebo IPX056 - Spasticity, Multiple Sclerosis | Phase 2 | Completed | Impax Laboratories, LLC | 23 | 2009-04-01 | 2019-11-06 |
| Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity baclofen - Spasticity, Cerebral Palsy | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 61 | 2008-11-01 | 2011-12-06 |
| A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID - Muscle Spasticity | Phase 2 | Completed | XenoPort, Inc. | 37 | 2007-12-01 | 2021-02-21 |
| Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity Tizanidine (sublingual or oral) - Muscle Spasticity | Phase 1 / Phase 2 | Completed | Teva GTC | 20 | 2006-12-01 | 2009-01-21 |
| Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease Levetiracetam - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Duke University | 20 | 2006-05-01 | 2013-06-19 |
| Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment Botulinum Toxin Type A, Placebo - Stroke, Muscle Spasticity | Phase 2 | Completed | Allergan | 62 | 2004-03-01 | 2008-05-28 |
Showing 20 of 25. Sign in to see all of them.
Stroke (7) · Multiple Sclerosis (6) · Cerebral Palsy (4) · Motor Neuron Disease (3) · Amyotrophic Lateral Sclerosis (2) · Marijuana Abuse (2) · Contracture (1) · Ichthyosis (1) · Intellectual Disability (1) · Motor Activity (1) · Muscle Cramp (1) · Muscular Atrophy, Spinal (1) · Pain (1) · Paraplegia (1)
Muscle Hypertonia (25) · Muscular Diseases (25) · Musculoskeletal Diseases (25) · Nervous System Diseases (25) · Neurologic Manifestations (25) · Neuromuscular Manifestations (25) · Pathological Conditions, Signs and Symptoms (25) · Signs and Symptoms (25) · Central Nervous System Diseases (14) · Brain Diseases (11) · Cardiovascular Diseases (7) · Cerebrovascular Disorders (7) · Vascular Diseases (7) · Autoimmune Diseases (6) · Autoimmune Diseases of the Nervous System (6)
Botulinum Toxins, Type A (5) · BID protein, human (2) · tizanidine (2) · 4-Aminopyridine (1) · ADX-629 (1) · Administration, Sublingual (1) · Baclofen (1) · Levetiracetam (1) · Low-Level Light Therapy (1) · Moxifloxacin (1) · Sodium Chloride (1) · Sugars (1) · nabilone (1) · nabiximols (1)
Allergan (3) · Acorda Therapeutics (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Auxilium Vitae Volterra (1) · Canbex Therapeutics Ltd (1) · Center for Medicinal Cannabis Research (1) · Dr. Gabriel Zeilig (1) · Duke University (1) · Impax Laboratories, LLC (1) · Northwell Health (1) · Ospedale San Raffaele (1) · Sandwell & West Birmingham Hospitals NHS Trust (1) · Sun Pharma Advanced Research Company Limited (1) · Teva GTC (1) · Universidade Federal de Pernambuco (1)
United States (15) · Brazil (3) · Canada (3) · Israel (2) · United Kingdom (2) · Czechia (1) · Hungary (1) · Italy (1) · Poland (1) · Russia (1) · Ukraine (1)
Anand D Pandyan, PhD (1) · Ariane Zoll (1) · Arnon Karni, MD (1) · Dr Rachel Farrell (1) · Gabriel Zeilig, M.D (1) · Giancarlo Comi, MD (1) · Janice Brunstrom, MD (1) · Jody Corey-Bloom, M.D., Ph.D. (1) · Karen D. Ethans, MD (1) · Lucinda L Hugos, MS (1) · Mathews Adera, MD (1)
PMID 24607242, PMID 28867665, PMID 30554828, PMID 32232101, PMID 33040610, PMID 36325678